Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
08/29/2020 at 1:00 - 2:00 PM ET
Credit Type(s):
  • CME / AMA PRA Category 1 Credit™


Saturday, August 29, 2020
1:00 – 2:00 PM ET (12:00 Noon – 1:00 PM CT / 10:00 – 11:00 AM PT)
Program Faculty: Susmita Parashar, MD; Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA
Hosted by: American Association of Cardiologists of Indian Origin (AACIO)

It is estimated that 720,000 Americans will have a new coronary event and 335,000 will have a recurrent event this year. Guidelines recommend that these patients receive dual antiplatelet therapy (DAPT) with low-dose ASA and a platelet P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor). While there is agreement that low-dose ASA therapy should be continued indefinitely, research continues to lead to modifications of the recommendations for P2Y12 receptor antagonists. To address this, in 2016 the ACC and AHA jointly published a focused guideline update on the use of DAPT in CAD. However, many clinicians are not yet following these recommendations, either because they are not familiar with them or because they are skeptical about the applicability of randomized clinical trials to their practices.

Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond will review the 2016 ACC/AHA guideline update for the use of DAPT in CAD and outline the real-world evidence for these recommendations. In addition, the activity will discuss the findings from studies completed after the guidelines were published that clinicians may find useful when developing individualized DAPT management strategies for their patients with CAD.


Welcome and Introductions
Guidelines on the Use of DAPT in CAD
What’s New Since the Guidelines?
Patient Education


This activity is intended for cardiologists who manage patients at risk for or with CAD.


This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Apply the 2016 ACC/AHA guideline focused update on DAPT recommendations when developing individualized management plans for patients with CAD
  • Consider the results of recent clinical trials investigating the optimal management of DAPT when creating management plans for patients with CAD
  • Identify validated tools that can be used to individualize DAPT therapy


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of North Texas Health Science Center and Rockpointe. The University of North Texas Health Science Center is accredited by the ACCME to provide continuing medical education for physicians.


The University of North Texas Health Science Center designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA
Associate Professor of Medicine
Director of Health Services Research
Duke University
Durham, NC
Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA is an Associate Professor of Medicine with Tenure in Cardiology at Duke University. An undergraduate of Yale University, she received her medical doctorate from Harvard Medical School and also holds an MSc degree in molecular biochemistry/biophysics from Yale University and an MHS degree in clinical research from Duke University. She joined the faculty at Duke University in 2008.

Dr. Wang is a health services researcher with expertise in implementation science and pragmatic clinical trials. She has led several cardiovascular clinical trials and registries at the Duke Clinical Research Institute (DCRI) that have focused on comparative effectiveness and safety, health disparities, care quality assessment and quality improvement. To date, she has published more than 250 manuscripts on these topics. She was the Principal Investigator of the ARTEMIS randomized clinical trial studying the impact of copayment reduction on antiplatelet medication adherence and outcomes after myocardial infarction. She has lectured widely on the use of “big data” to identify treatment gaps for intervention and has led projects using data solutions to design and implement quality-improvement initiatives. In addition, she is interested in evolving the platform for research to improve site and patient recruitment, innovate longitudinal patient follow-up, enrich the collection of patient-reported outcomes, pragmatically adjudicate clinical events of interest, and add important health economic insights.

Dr. Wang chaired the American Heart Association’s Quality of Care and Outcomes Research Council from 2017-2019, and serves on many task forces, committees, and writing groups for the American Heart Association, American College of Cardiology, and American College of Physicians. She is an Associate Editor of the JAMA Internal Medicine journal. She is the Director of Health Services and Outcomes Research at the DCRI and remains a practicing noninvasive cardiologist with both inpatient and outpatient responsibilities.
Marlene S. Williams, MD, FACC
Director, Cardiac Intensive Care Unit
Johns Hopkins Bayview Medical Center
Associate Professor of Medicine
Division of Cardiology
Johns Hopkins University
Baltimore, MD
Marlene S. Williams, MD, FACC is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine. Her research centers on coronary atherosclerosis and platelet function, and her particular focus is on platelet function as it relates to the acute coronary syndrome. Dr. Williams has examined platelet function and its correlation to platelet functional genomics and runs a platelet physiology laboratory on the Johns Hopkins Bayview campus. The goal for her cardiovascular platelet laboratory has been to identify the etiology of platelet dysfunction in many disease states and apply methods that may improve this dysfunction and eventually be translated to therapies for patients with cardiovascular disease.

She was the recipient of a National Institutes of Health (NIH) Career Mentored Award (K23) examining platelet functional genomics and an NIH RO1 Award addressing platelet serotonin signaling in depression and heart disease. Dr. Williams has several publications covering platelet functional changes in settings of interventional cardiology, acute coronary syndrome, and heart disease and depression. She has participated in several National Heart, Lung, and Blood Institute (NHLBI) advisory committees, review groups, and study sections.

Dr. Williams received her undergraduate degree in biochemistry from McGill University. She earned a medical degree from the Columbia University College of Physicians and Surgeons and completed a residency at Johns Hopkins Hospital. Dr. Williams was a cardiology fellow at Mount Sinai Hospital and Johns Hopkins Hospital and is currently Director of the Cardiac Intensive Care Unit at Johns Hopkins Bayview Medical Center.


All information contained within this activity is intended for educational purposes only. Physicians and other healthcare professionals are encouraged to consult other sources and confirm the information contained in this activity. No single reference or service can take the place of medical training, education, and experience. This activity does not define a standard of care, nor is it intended to dictate an exclusive course of management. This information should not substitute for a visit or consultation with a healthcare provider.


In accordance with the appropriate accrediting bodies, all planners, teachers, and authors with control over activity content are required to disclose to the provider any relevant financial relationships (those held by the planner or significant other, currently or within the last 12 months) with commercial interests. Accredited providers are required to provide this information and disclosures will be provided at the activity. Disclosures will be made known to participants prior to the start of the program.


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT There is no fee for this activity. To receive credit, participants must register, view the live CME/CE activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


Jointly provided by University of North Texas Health Science Center and Rockpointe

Physician CME


This program is conducted in collaboration with Mended Hearts.


This program is supported by an unrestricted educational grant from AstraZeneca.


Evidence-based Pain Management: Addressing the Growing Role of Nurse Practitioners and Physician Assistants in Managing Patients with Acute and Chronic Pain

Learn More

Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?

Learn More

Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy